Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A

Journal of Pharmacy and Pharmacology

Volumn 50, Issue 9, 1998, Pages 997-1004

  Von Moltke, Lisa L ^a   Greenblatt, David J ^a   Grassi, Jeffrey M ^a   Granda, Brian W ^a   Venkatakrishnan, Karthlk ^a   Schmider, Jürgen ^a   Harmatz, Jerold S ^a   Shader, Richard I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHOXYMORPHINAN; CYTOCHROME C; DEXTROMETHORPHAN; DEXTRORPHAN; DRUG METABOLITE; KETOCONAZOLE; OMEPRAZOLE; QUINIDINE; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; LIVER MICROSOME; LYMPHOBLASTOID CELL;

EID: 0031689333     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1998.tb06914.x     Document Type: Article

References (27)

1. Bertz, R. J., Granneman, G. R. (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32: 210-258
2. Crespi, C. L. (1995) Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv. Drug Res. 26: 179-235
3. Dayer, P., Leeman, T., Striberni, R. (1989) Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P450 DB1 activity. Clin. Pharmacol. Ther. 45: 34-40
4. Ducharme, J., Abdullah, S., Wainer, I. W. (1996) Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J. Chromatogr. B 678: 113-128
5. Engel, G., Hofmann, U., Kroemer, H. K. (1996) Prediction of CYP2D6-mediated polymorphic drug metabolism (sparteine type) based on in vitro investigations. J. Chromatogr. B 678: 93-103
6. Gorski, J. C., Jones, D. R., Wrighton, S. A., Hall, S. D. (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes. Biochem. Pharmacol. 48: 173-182
7. Greenblatt, D. J., von Moltke, L. L. (1997) Can in vitro models predict drug interactions in vivo? A review of methods, problems, and successes. In: Hori, W. (ed.) Drug-Drug Interactions: Analyzing In vitro-In Vivo Correlations. Southboro, MA, International Business Communications 2.2.1-2.2.28
8. Inoue, K., Yamazaki, H., Imiya, K., Akasaka, S., Guengerich, F. P., Shimada, T. (1997) Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7: 103-113
9. Jacqz-Aigrain, E., Funck-Brentano, C., Cresteil, T. (1993) CYP2D6-and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3: 197-204
10. Jones, D. R., Gorski, J. C., Haehner, B. D., O'Mara, E. M., Hall, S. D. (1996a) Determination of cytochrome P450 3A4/ 5 activity in vivo with dextromethorphan N-demethylation. Clin. Pharmacol. Ther. 60: 374-384
11. Jones, D. R., Gorski, J. C., Hamman, M. A., Hall, S. D. (1996b) Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity. J. Chromatogr. B 678: 105-111
12. Kerry, N. L., Somogyi, A. A., Bochner, F., Mikus, G. (1994) The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. Br. J. Clin. Pharmacol. 38: 243-248
13. Kobayashi, K., Chiba, K., Yagi, T., Shimada, T., Taniguchi, T., Horie, T., Yamamoto, T., Ishizaki, T., Kuroiwa, Y. (1997) Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J. Pharmacol. Exp. Ther. 280: 927-933
14. Kroemer, H. K., Eichelbaum, M. (1995) Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci. 56: 2285-2298
15. 14C] dextromethorphan as substrate. Methods Enzymol. 272: 186-195
16. Schadel, M., Wu, D., Otton, S. V., Kalow, W., Sellers, E. M. (1995) Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J. Clin. Psychopharmacol. 15: 263-269
17. Schmider, J., Greenblatt, D. J., von Moltke, L. L., Harmatz, J. S., Shader, R. I. (1996) Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O-and N-demethylation. Br. J. Clin. Pharmacol. 41: 339-343
18. Schmider, J., Greenblatt, D. J., Fogelman, S. M., von Moltke, L. L., Shader, R. I. (1997) Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6, 3A3/4, with a possible role of 2E1. Biopharmaceut. Drug Dispos 18: 227-240
19. Shimada, T., Yamazaki, H., Mayumi, M., Inui, Y., Guengerich, F. P. (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-423
20. Venkatakrishnan, K., Greenblatt, D. J., von Moltke, L. L., Schmider, J., Harmatz, J. S., Shader, R. I. (1998) Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J. Clin. Pharmacol. 38: 112-121
21. von Moltke, L. L., Greenblatt, D. J., Cotreau-Bibbo, M. M., Haimatz, J. S, Shader, R. I. (1994) Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br. J. Clin. Pharmacol. 38: 23-31
22. von Moltke, L. L., Greenblatt, D. J., Court, M. H., Duan, S. X., Harmatz, J. S., Shader, R. I. (1995a) Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J. Clin. Psychopharmacol. 15: 125-131
23. von Moltke, L. L., Greenblatt, D. J., Schmider, J., Harmatz, J. S., Shader, R. I. (1995b) Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin. Pharmacokinet. 29 (Suppl. 1): 33-43
24. von Moltke, L. L., Greenblatt, D. J., Duan, S. X., Schmider, J., Kudchadker, L., Fogelman, S. M., Harmatz, J. S., Shader, R. I. (1996a) Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine. Psychopharmacology 128: 398-407
25. von Moltke, L. L., Greenblatt, D. J., Harmatz, J. S., Duan, S. X., Harrel, L. M., Cotreau-Bibbo, M. M., Pritchard, G. A., Wright, C. E., Shader, R. I. (1996b) Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J. Pharmacol. Exp. Ther. 276: 370-379
26. von Moltke, L. L., Greenblatt, D. J., Schmider, J., Duan, S. X., Wright, C. E., Harmatz, J. S., Shader, R. I. (1996c) Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J. Clin. Pharmacol. 36: 783-791
27. von Moltke, L. L., Greenblatt, D. J., Schmider, J., Wright, C. E., Harmatz, J. S., Shader, R. I. (1998) In vitro approaches to predicting drug interactions in vivo. Biochem. Pharmacol. 55: 113-122